Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Merck Sharp & Dohme LLC
Domenica Lorusso; Yang Xiang; Kosei Hasegawa; Giovanni Scambia; Manuel Leiva; Pier Ramos-Elias; Alejandro Acevedo; Jakub Cvek; Leslie Randall; Andrea Juliana Pereira de Santana Gomes; Fernando Contreras Mejía; Limor Helpman; Hüseyin Akıllı; Jung-Yun Lee; Valeriya Saevets; Flora Zagouri; Lucy Gilbert; Jalid Sehouli; Ekkasit Tharavichitkul; Kristina Lindemann; Nicoletta Colombo; Chih-Long Chang; Marketa Bednarikova; Hong Zhu; Ana Oaknin; Melissa Christiaens; Edgar Petru; Tomoka Usami; Peng Liu; Karin Yamada; Sarper Toker; Stephen M Keefe; Sandro Pignata; Linda R Duska; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators